Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities Conference
Nuwellis (Nasdaq: NUWE), a medical technology company focused on treating fluid overload, has announced its participation in the Third Annual ROTH Healthcare Opportunities Conference. The event is scheduled for Wednesday, October 9, 2024.
President and CEO Nestor Jaramillo will represent Nuwellis at the conference. Investor presentations and related materials will be accessible on the company's website in the investor relations section.
Interested parties can attend the conference and meet with Nuwellis representatives by contacting their ROTH representative, submitting an online registration request, or reaching out to Vivian Cervantes at Gilmartin Group via ir@nuwellis.com.
Nuwellis (Nasdaq: NUWE), un'azienda di tecnologia medicale focalizzata nel trattamento dell'eccesso di liquidi, ha annunciato la sua partecipazione alla Terza Conferenza Annuale ROTH sulle Opportunità Sanitarie. L'evento si svolgerà il mercoledì 9 ottobre 2024.
Il Presidente e CEO Nestor Jaramillo rappresenterà Nuwellis alla conferenza. Le presentazioni per gli investitori e i materiali correlati saranno accessibili sul sito web dell'azienda nella sezione relazioni con gli investitori.
Le parti interessate possono partecipare alla conferenza e incontrare i rappresentanti di Nuwellis contattando il loro rappresentante ROTH, inviando una richiesta di registrazione online o contattando Vivian Cervantes del Gilmartin Group all'indirizzo ir@nuwellis.com.
Nuwellis (Nasdaq: NUWE), una empresa de tecnología médica centrada en el tratamiento de la sobrecarga de fluidos, ha anunciado su participación en la tercera Conferencia Anual de Oportunidades de Salud ROTH. El evento está programado para el miércoles 9 de octubre de 2024.
El Presidente y CEO Nestor Jaramillo representará a Nuwellis en la conferencia. Las presentaciones para inversores y materiales relacionados estarán disponibles en la sección de relaciones con inversores del sitio web de la empresa.
Las partes interesadas pueden asistir a la conferencia y reunirse con los representantes de Nuwellis contactando a su representante de ROTH, enviando una solicitud de registro en línea o comunicándose con Vivian Cervantes del Gilmartin Group a través de ir@nuwellis.com.
Nuwellis (Nasdaq: NUWE), 체액 과부하 치료에 중점을 둔 의료 기술 회사는 제3회 연례 ROTH 헬스케어 기회 컨퍼런스에 참여할 것이라고 발표했습니다. 이 행사는 2024년 10월 9일 수요일에 예정되어 있습니다.
회장 겸 CEO Nestor Jaramillo가 컨퍼런스에서 Nuwellis를 대표할 것입니다. 투자자 발표 및 관련 자료는 회사 웹사이트의 투자자 관계 섹션에서 접근할 수 있습니다.
관심 있는 당사자들은 ROTH 대표에게 연락하거나 온라인 등록 요청서를 제출하거나 Vivian Cervantes에게 ir@nuwellis.com을 통해 Gilmartin Group에 연락하여 컨퍼런스에 참석하고 Nuwellis 대표들과 만날 수 있습니다.
Nuwellis (Nasdaq: NUWE), une entreprise de technologie médicale spécialisée dans le traitement de la surcharge liquidienne, a annoncé sa participation à la Troisième Conférence Annuelle ROTH sur les Opportunités en Santé. L'événement est prévu pour le mercredi 9 octobre 2024.
Le Président et CEO Nestor Jaramillo représentera Nuwellis lors de la conférence. Les présentations pour les investisseurs et les documents associés seront accessibles sur le site Web de l'entreprise dans la section des relations avec les investisseurs.
Les parties intéressées peuvent assister à la conférence et rencontrer des représentants de Nuwellis en contactant leur représentant ROTH, en soumettant une demande d'inscription en ligne ou en rejoignant Vivian Cervantes de Gilmartin Group à l'adresse ir@nuwellis.com.
Nuwellis (Nasdaq: NUWE), ein Medizintechnikunternehmen, das sich auf die Behandlung von Flüssigkeitsüberlastung konzentriert, hat seine Teilnahme an der Dritten jährlichen ROTH Gesundheitschancen-Konferenz bekannt gegeben. Die Veranstaltung findet am Mittwoch, den 9. Oktober 2024 statt.
Präsident und CEO Nestor Jaramillo wird Nuwellis auf der Konferenz vertreten. Investorenpräsentationen und verwandte Materialien sind im Bereich Investor Relations auf der Website des Unternehmens verfügbar.
Interessierte Parteien können an der Konferenz teilnehmen und sich mit Vertretern von Nuwellis treffen, indem sie ihren ROTH-Vertreter kontaktieren, eine Online-Registrierungsanfrage einreichen oder sich an Vivian Cervantes von der Gilmartin Group unter ir@nuwellis.com wenden.
- None.
- None.
MINNEAPOLIS, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to announce that President and Chief Executive Officer Nestor Jaramillo will participate in ROTH Capital Partners’ third annual ROTH Healthcare Opportunities Conference on Wednesday, October 9, 2024.
Investor presentations and other materials used at the conference will be available on the investor relations section of Nuwellis’ website. Parties interested in attending the conference and meeting with Nuwellis may contact their ROTH representative, submit a registration request online, or contact Vivian Cervantes, Gilmartin Group, at ir@nuwellis.com.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or X.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
CONTACTS
Investors:
Vivian Cervantes
Gilmartin Group
ir@nuwellis.com
FAQ
When is Nuwellis (NUWE) presenting at the ROTH Healthcare Opportunities Conference?
Who will represent Nuwellis (NUWE) at the ROTH Healthcare Opportunities Conference?
How can investors access Nuwellis (NUWE) presentation materials from the ROTH conference?
How can interested parties attend the ROTH conference and meet with Nuwellis (NUWE)?
